BG108363A - Крипто блокиращи антитела и тяхното използване - Google Patents

Крипто блокиращи антитела и тяхното използване Download PDF

Info

Publication number: BG108363A
Authority: BG; Bulgaria
Prior art keywords: antibody; crypto; antibodies; tumor; epitope
Prior art date: 2001-04-26

Application number

BG108363A

Other languages

Bulgarian (bg)

English (en)

Inventor

Michele Sanicola-Nadel

Kevin Williams

Susan Schiffer

Paul Rayhorn

Original Assignee

Biogen, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-26

Filing date

2003-11-14

Publication date

2004-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501437&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG108363(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-11-14 Application filed by Biogen, Inc. filed Critical Biogen, Inc.

2004-09-30 Publication of BG108363A publication Critical patent/BG108363A/bg

Links

230000000903 blocking effect Effects 0.000 title claims abstract description 13
101100369076 Mus musculus Tdgf1 gene Proteins 0.000 title abstract 10
238000000034 method Methods 0.000 claims abstract description 35
230000011664 signaling Effects 0.000 claims abstract description 27
230000004614 tumor growth Effects 0.000 claims abstract description 26
230000003993 interaction Effects 0.000 claims abstract description 21
102100034134 Activin receptor type-1B Human genes 0.000 claims abstract description 12
101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 claims abstract description 12
210000004027 cell Anatomy 0.000 claims description 86
206010028980 Neoplasm Diseases 0.000 claims description 48
241000282414 Homo sapiens Species 0.000 claims description 42
239000000203 mixture Substances 0.000 claims description 38
230000027455 binding Effects 0.000 claims description 35
108050002150 EGF-like domains Proteins 0.000 claims description 24
102000012545 EGF-like domains Human genes 0.000 claims description 24
235000018417 cysteine Nutrition 0.000 claims description 23
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 23
210000004881 tumor cell Anatomy 0.000 claims description 20
230000004565 tumor cell growth Effects 0.000 claims description 20
238000000338 in vitro Methods 0.000 claims description 16
125000000539 amino acid group Chemical group 0.000 claims description 14
108020003175 receptors Proteins 0.000 claims description 14
102000005962 receptors Human genes 0.000 claims description 14
238000012360 testing method Methods 0.000 claims description 13
238000001727 in vivo Methods 0.000 claims description 12
210000001072 colon Anatomy 0.000 claims description 11
210000003932 urinary bladder Anatomy 0.000 claims description 11
239000002246 antineoplastic agent Substances 0.000 claims description 10
210000003679 cervix uteri Anatomy 0.000 claims description 10
239000003446 ligand Substances 0.000 claims description 10
210000004072 lung Anatomy 0.000 claims description 10
210000001672 ovary Anatomy 0.000 claims description 10
210000000496 pancreas Anatomy 0.000 claims description 10
210000002784 stomach Anatomy 0.000 claims description 10
210000004291 uterus Anatomy 0.000 claims description 10
210000000481 breast Anatomy 0.000 claims description 9
229940127089 cytotoxic agent Drugs 0.000 claims description 9
210000004408 hybridoma Anatomy 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
210000001550 testis Anatomy 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 8
238000002512 chemotherapy Methods 0.000 claims description 5
238000003018 immunoassay Methods 0.000 claims description 4
206010006187 Breast cancer Diseases 0.000 claims description 3
208000026310 Breast neoplasm Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
230000004663 cell proliferation Effects 0.000 claims 1
239000012634 fragment Substances 0.000 abstract description 11
230000001225 therapeutic effect Effects 0.000 abstract description 9
108090000623 proteins and genes Proteins 0.000 description 47
235000018102 proteins Nutrition 0.000 description 42
102000004169 proteins and genes Human genes 0.000 description 42
238000011282 treatment Methods 0.000 description 28
241001465754 Metazoa Species 0.000 description 25
239000000427 antigen Substances 0.000 description 19
108091007433 antigens Proteins 0.000 description 19
102000036639 antigens Human genes 0.000 description 19
230000000694 effects Effects 0.000 description 19
238000003556 assay Methods 0.000 description 17
239000002299 complementary DNA Substances 0.000 description 15
150000001875 compounds Chemical class 0.000 description 15
239000002609 medium Substances 0.000 description 15
108060001084 Luciferase Proteins 0.000 description 14
239000005089 Luciferase Substances 0.000 description 14
230000002159 abnormal effect Effects 0.000 description 14
238000002965 ELISA Methods 0.000 description 13
238000004458 analytical method Methods 0.000 description 12
108090000765 processed proteins & peptides Proteins 0.000 description 12
229920001817 Agar Polymers 0.000 description 11
241000699666 Mus <mouse, genus> Species 0.000 description 11
239000008272 agar Substances 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 11
239000011534 wash buffer Substances 0.000 description 11
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
241000699670 Mus sp. Species 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
230000012010 growth Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 9
230000037396 body weight Effects 0.000 description 9
238000005259 measurement Methods 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
239000000872 buffer Substances 0.000 description 8
229920001184 polypeptide Polymers 0.000 description 8
239000000243 solution Substances 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
108060003951 Immunoglobulin Proteins 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
102000018358 immunoglobulin Human genes 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
230000002381 testicular Effects 0.000 description 7
201000011510 cancer Diseases 0.000 description 6
238000012216 screening Methods 0.000 description 6
229940009456 adriamycin Drugs 0.000 description 5
238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
230000002018 overexpression Effects 0.000 description 5
230000037361 pathway Effects 0.000 description 5
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
239000000758 substrate Substances 0.000 description 5
238000001262 western blot Methods 0.000 description 5
241000282412 Homo Species 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
229960004316 cisplatin Drugs 0.000 description 4
230000009260 cross reactivity Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
230000004927 fusion Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
229960004768 irinotecan Drugs 0.000 description 4
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 4
108010082117 matrigel Proteins 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
229910052697 platinum Inorganic materials 0.000 description 4
230000006916 protein interaction Effects 0.000 description 4
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000001488 sodium phosphate Substances 0.000 description 4
229910000162 sodium phosphate Inorganic materials 0.000 description 4
239000007787 solid Substances 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
230000009466 transformation Effects 0.000 description 4
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
101000969593 Caenorhabditis elegans Modifier of protein aggregation 4 Proteins 0.000 description 3
101000872083 Danio rerio Delta-like protein C Proteins 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
-1 cis-platinum) Chemical compound 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
238000002513 implantation Methods 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
238000011580 nude mouse model Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000007781 signaling event Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000001890 transfection Methods 0.000 description 3
108020004414 DNA Proteins 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
241000288906 Primates Species 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
108700019146 Transgenes Proteins 0.000 description 2
229940122803 Vinca alkaloid Drugs 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
229940045799 anthracyclines and related substance Drugs 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000004163 cytometry Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
108020001580 protein domains Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
229950010131 puromycin Drugs 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000012089 stop solution Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
101150101604 ACVR1B gene Proteins 0.000 description 1
101710117545 C protein Proteins 0.000 description 1
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
239000012624 DNA alkylating agent Substances 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
229940123414 Folate antagonist Drugs 0.000 description 1
206010061968 Gastric neoplasm Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
101000898072 Homo sapiens Calretinin Proteins 0.000 description 1
101000806138 Homo sapiens Dehydrogenase/reductase SDR family member 4 Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102100026894 Lymphotoxin-beta Human genes 0.000 description 1
108090000362 Lymphotoxin-beta Proteins 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
230000010632 Transcription Factor Activity Effects 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
102000013814 Wnt Human genes 0.000 description 1
108050003627 Wnt Proteins 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000012801 analytical assay Methods 0.000 description 1
239000003098 androgen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
229940127093 camptothecin Drugs 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000013024 dilution buffer Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
231100000776 exotoxin Toxicity 0.000 description 1
239000002095 exotoxin Substances 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
230000036541 health Effects 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
238000013427 histology analysis Methods 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
210000004457 myocytus nodalis Anatomy 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
208000025189 neoplasm of testis Diseases 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000004287 null lymphocyte Anatomy 0.000 description 1
150000002482 oligosaccharides Polymers 0.000 description 1
229940043515 other immunoglobulins in atc Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000010399 physical interaction Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
238000010079 rubber tapping Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
239000010409 thin film Substances 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
208000025421 tumor of uterus Diseases 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
208000024719 uterine cervix neoplasm Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG108363A 2001-04-26 2003-11-14 Крипто блокиращи антитела и тяхното използване BG108363A (bg)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US28678201P	2001-04-26	2001-04-26
US29302001P	2001-05-17	2001-05-17
US30109101P	2001-06-26	2001-06-26
US36700202P	2002-03-22	2002-03-22
PCT/US2002/011950 WO2002088170A2 (en)	2001-04-26	2002-04-17	Cripto blocking antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
BG108363A true BG108363A (bg)	2004-09-30

Family

ID=27501437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108363A BG108363A (bg)	2001-04-26	2003-11-14	Крипто блокиращи антитела и тяхното използване

Country Status (34)

Country	Link
US (6)	US7531174B2 (xx)
EP (3)	EP1390389B1 (xx)
JP (4)	JP4307845B2 (xx)
KR (1)	KR100592357B1 (xx)
CN (1)	CN100352501C (xx)
AR (3)	AR037223A1 (xx)
AT (2)	ATE420659T1 (xx)
BG (1)	BG108363A (xx)
BR (1)	BR0209254A (xx)
CA (2)	CA2443840C (xx)
CL (1)	CL2009002199A1 (xx)
CY (1)	CY1108960T1 (xx)
CZ (1)	CZ20033208A3 (xx)
DE (1)	DE60230868D1 (xx)
DK (1)	DK1390389T3 (xx)
EA (1)	EA007469B1 (xx)
EE (1)	EE200300528A (xx)
ES (1)	ES2321065T3 (xx)
GE (1)	GEP20074091B (xx)
HK (1)	HK1058935A1 (xx)
HU (1)	HUP0501113A3 (xx)
IS (1)	IS2662B (xx)
MX (1)	MXPA03009797A (xx)
MY (2)	MY157382A (xx)
NO (1)	NO20034805L (xx)
NZ (1)	NZ566268A (xx)
PL (1)	PL207087B1 (xx)
PT (1)	PT1390389E (xx)
RS (2)	RS20110024A (xx)
SG (1)	SG157951A1 (xx)
SI (1)	SI1390389T1 (xx)
SK (1)	SK14432003A3 (xx)
TR (1)	TR200301846T2 (xx)
WO (1)	WO2002088170A2 (xx)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPR395801A0 (en)	2001-03-26	2001-04-26	Austin Research Institute, The	Antibodies against cancer
US20090123470A1 (en) *	2001-03-26	2009-05-14	The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd.	Antibodies Against Cancer
US7582299B2 (en)	2001-04-26	2009-09-01	Biogen Idec Ma Inc.	Cripto-specific antibodies
EA007469B1 (ru)	2001-04-26	2006-10-27	Байоджен Айдек Эмэй Инк.	Антитела, блокирующие cripto, и их применения
EP1494693B1 (en) *	2002-03-22	2010-12-08	Biogen Idec MA Inc.	Cripto-specific antibodies
JP5068072B2 (ja)	2003-06-27	2012-11-07	バイオジェン・アイデック・エムエイ・インコーポレイテッド	連結ペプチドを含む改変された結合分子
DE602004022315D1 (de) *	2003-09-15	2009-09-10	Res Dev Foundation	Cripto-antagonismus von activin und tgf-b signalisierung
US7498298B2 (en)	2003-11-06	2009-03-03	Seattle Genetics, Inc.	Monomethylvaline compounds capable of conjugation to ligands
WO2005047327A2 (en)	2003-11-12	2005-05-26	Biogen Idec Ma Inc.	NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CA2567520A1 (en)	2004-06-01	2005-12-15	Genentech, Inc.	Maytansinoid-antibody conjugates
SI1791565T1 (sl)	2004-09-23	2016-08-31	Genentech, Inc.	Cisteinsko konstruirana protitelesa in konjugati
US20100111856A1 (en)	2004-09-23	2010-05-06	Herman Gill	Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006074399A2 (en)	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Multispecific binding molecules comprising connecting peptides
NZ556788A (en)	2005-01-05	2011-03-31	Biogen Idec Inc	Humanized CRIPTO binding molecules with CDRs from murine B3F6
WO2008014426A2 (en)	2006-07-28	2008-01-31	Children's Memorial Hospital	Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
CN101970001A (zh) *	2007-06-01	2011-02-09	比奥根艾迪克Ma公司	Cripto结合分子
WO2009131852A1 (en) *	2008-04-21	2009-10-29	Merck & Co., Inc.	Pancreatic beta-cell mass biomarker
CN102272157B (zh) *	2008-11-07	2015-11-25	研究发展基金会	用于抑制cripto/grp78复合物形成和信号的组合物和方法
US8470980B2 (en)	2009-09-09	2013-06-25	Centrose, Llc	Extracellular targeted drug conjugates
MA34277B1 (fr)	2010-04-15	2013-06-01	Spirogen Developments Sarl	Pyrrolobenzodiazépines et conjugués de celles-ci
US9000130B2 (en)	2010-06-08	2015-04-07	Genentech, Inc.	Cysteine engineered antibodies and conjugates
US20120121615A1 (en)	2010-11-17	2012-05-17	Flygare John A	Alaninyl maytansinol antibody conjugates
DK3138581T3 (en)	2011-03-17	2019-04-15	Univ Birmingham	REDIRECTED IMMUNTERY
SG194567A1 (en)	2011-04-21	2013-12-30	Seattle Genetics Inc	Novel binder-drug conjugates (adcs) and their use
CA2833212C (en)	2011-05-12	2020-06-09	Genentech, Inc.	Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
WO2013012733A1 (en)	2011-07-15	2013-01-24	Biogen Idec Ma Inc.	Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
AU2012322607B2 (en)	2011-10-14	2017-02-16	Genentech, Inc.	Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en)	2012-03-02	2013-09-06	Genentech, Inc.	Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
TR201815418T4 (tr)	2012-10-12	2018-11-21	Adc Therapeutics Sa	Pirrolobenzodiazepin -anti-psma antikor konjugatları.
SI2906296T1 (en)	2012-10-12	2018-06-29	Adc Therapeutics Sa	Pyrrolobenzodiazepine-antibody conjugates
CN104837502B (zh)	2012-10-12	2018-08-10	麦迪穆有限责任公司	吡咯并苯并二氮杂卓及其结合物
ES2680153T3 (es)	2012-10-12	2018-09-04	Adc Therapeutics Sa	Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
WO2014057120A1 (en)	2012-10-12	2014-04-17	Adc Therapeutics Sàrl	Pyrrolobenzodiazepine-antibody conjugates
PL2906298T3 (pl)	2012-10-12	2019-04-30	Adc Therapeutics Sa	Koniugaty pirolobenzodiazepina - przeciwciało
PL2906251T3 (pl)	2012-10-12	2018-02-28	Adc Therapeutics Sa	Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
AU2013366493B2 (en)	2012-12-21	2017-08-24	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
CN110627797A (zh)	2012-12-21	2019-12-31	麦迪穆有限责任公司	用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
BR112015021965B1 (pt)	2013-03-13	2022-05-03	Medimmune Limited	Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos
CA2901941C (en)	2013-03-13	2020-04-07	Spirogen Sarl	Pyrrolobenzodiazepines and conjugates thereof
KR102066319B1 (ko)	2013-03-13	2020-01-14	메디뮨 리미티드	피롤로벤조디아제핀 및 그의 컨쥬게이트
WO2015023355A1 (en)	2013-08-12	2015-02-19	Genentech, Inc.	1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054986B1 (en)	2013-10-11	2019-03-20	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en)	2013-10-11	2013-11-27	Spirogen Sarl	Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en)	2013-10-11	2018-04-24	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en)	2013-10-11	2018-07-03	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
KR20170042495A (ko)	2013-12-16	2017-04-19	제넨테크, 인크.	펩티드모방체 화합물 및 그의 항체-약물 접합체
KR20160092024A (ko)	2013-12-16	2016-08-03	제넨테크, 인크.	1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
MX371092B (es)	2013-12-16	2020-01-16	Genentech Inc	Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
JP6721507B2 (ja)	2013-12-23	2020-07-15	バイエル・ファルマ・アクティエンゲゼルシャフト	Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ）
WO2016037644A1 (en)	2014-09-10	2016-03-17	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
CN107108724A (zh)	2014-09-12	2017-08-29	豪夫迈·罗氏有限公司	半胱氨酸改造抗体和缀合物
GB201416112D0 (en)	2014-09-12	2014-10-29	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en)	2014-09-12	2018-12-11	Genentech, Inc.	Anthracycline disulfide intermediates, antibody-drug conjugates and methods
AU2015317653A1 (en)	2014-09-17	2017-04-06	Genentech, Inc.	Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
WO2016083468A1 (en)	2014-11-25	2016-06-02	Adc Therapeutics Sa	Pyrrolobenzodiazepine-antibody conjugates
CN107206101B (zh)	2014-12-03	2021-06-25	基因泰克公司	季铵化合物及其抗体-药物缀合物
CA2980611A1 (en) *	2015-04-07	2016-10-13	Paranta Biosciences Limited	A method of treating neoplasias
GB201506411D0 (en)	2015-04-15	2015-05-27	Bergenbio As	Humanized anti-axl antibodies
GB201506402D0 (en)	2015-04-15	2015-05-27	Berkel Patricius H C Van And Howard Philip W	Site-specific antibody-drug conjugates
WO2016207089A1 (de)	2015-06-22	2016-12-29	Bayer Pharma Aktiengesellschaft	Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
MA43345A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017060322A2 (en)	2015-10-10	2017-04-13	Bayer Pharma Aktiengesellschaft	Ptefb-inhibitor-adc
MA43354A (fr)	2015-10-16	2018-08-22	Genentech Inc	Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr)	2015-10-20	2018-08-29	Genentech Inc	Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en)	2016-01-26	2016-03-09	Medimmune Ltd	Pyrrolobenzodiazepines
GB201602359D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
CN116059390A (zh)	2016-03-24	2023-05-05	拜耳制药股份公司	具有酶促可裂解基团的细胞毒性活性物质的前药
EP4273551A3 (en)	2016-03-25	2024-01-17	F. Hoffmann-La Roche AG	Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en)	2016-04-29	2016-06-15	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en)	2016-05-20	2020-12-30	H. Hoffnabb-La Roche Ag	Protac antibody conjugates and methods of use
WO2017205741A1 (en)	2016-05-27	2017-11-30	Genentech, Inc.	Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN109476648B (zh)	2016-06-06	2022-09-13	豪夫迈·罗氏有限公司	司维司群抗体-药物缀合物和使用方法
WO2017216028A1 (en)	2016-06-15	2017-12-21	Bayer Pharma Aktiengesellschaft	Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
EP3496763A1 (en)	2016-08-11	2019-06-19	Genentech, Inc.	Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
EP3522933B1 (en)	2016-10-05	2021-12-15	F. Hoffmann-La Roche AG	Methods for preparing antibody drug conjugates
GB201617466D0 (en)	2016-10-14	2016-11-30	Medimmune Ltd	Pyrrolobenzodiazepine conjugates
CA3047522A1 (en)	2016-12-21	2018-06-28	Bayer Pharma Aktiengesellschaft	Specific antibody drug conjugates (adcs) having ksp inhibitors
EP3558386A1 (de)	2016-12-21	2019-10-30	Bayer Aktiengesellschaft	Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
IL291308B2 (en)	2016-12-21	2024-07-01	Bayer Pharma AG	Drug-antibody conjugates with enzymatically cleavable groups
SI3544636T1 (sl)	2017-02-08	2021-08-31	Adc Therapeutics Sa	Konjugati pirolobenzodiazepin-protitelo
GB201702031D0 (en)	2017-02-08	2017-03-22	Medlmmune Ltd	Pyrrolobenzodiazepine-antibody conjugates
ES2926144T3 (es)	2017-04-18	2022-10-24	Medimmune Ltd	Conjugados de pirrolobenzodiazepina
JP7408396B2 (ja)	2017-04-20	2024-01-05	アーデーセーセラピューティクスソシエテアノニム	併用療法
AU2018285562B2 (en)	2017-06-14	2024-01-18	Adc Therapeutics Sa	Dosage regimes for the administration of an anti-CD19 ADC
JP7220203B2 (ja)	2017-08-18	2023-02-09	メドイミューン・リミテッド	ピロロベンゾジアゼピン複合体
TW201920192A (zh)	2017-09-20	2019-06-01	韓商Ｐｈ製藥公司	泰蘭他汀（ｔｈａｉｌａｎｓｔａｔｉｎ）類似物
GB201803342D0 (en)	2018-03-01	2018-04-18	Medimmune Ltd	Methods
GB201806022D0 (en)	2018-04-12	2018-05-30	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
EP3801632A1 (en)	2018-06-01	2021-04-14	Eisai R&D Management Co., Ltd.	Splicing modulator antibody-drug conjugates and methods of use
GB201814281D0 (en)	2018-09-03	2018-10-17	Femtogenix Ltd	Cytotoxic agents
JP2022505450A (ja)	2018-10-24	2022-01-14	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	コンジュゲート化された化学的分解誘導物質および使用方法
WO2020123275A1 (en)	2018-12-10	2020-06-18	Genentech, Inc.	Photocrosslinking peptides for site specific conjugation to fc-containing proteins
MX2021005878A (es)	2018-12-13	2021-07-16	Eisai R&D Man Co Ltd	Modulador de empalme de herboxidieno de conjugados de anticuerpo-farmaco y metodos de uso.
WO2020131697A2 (en)	2018-12-17	2020-06-25	Revitope Limited	Twin immune cell engager
GB201901197D0 (en)	2019-01-29	2019-03-20	Femtogenix Ltd	G-A Crosslinking cytotoxic agents
GB2597532A (en)	2020-07-28	2022-02-02	Femtogenix Ltd	Cytotoxic compounds
WO2024138128A2 (en)	2022-12-23	2024-06-27	Genentech, Inc.	Cereblon degrader conjugates, and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ207394A (en) *	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5780029A (en)	1989-11-14	1998-07-14	New York Medical College	Antidiotypic monoclonal antibodies for treatment of melanoma
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5256643A (en)	1990-05-29	1993-10-26	The Government Of The United States	Human cripto protein
EP0546073B1 (en)	1990-08-29	1997-09-10	GenPharm International, Inc.	production and use of transgenic non-human animals capable of producing heterologous antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US5264557A (en)	1991-08-23	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Polypeptide of a human cripto-related gene, CR-3
US6063379A (en)	1993-12-09	2000-05-16	Centro De Inmunologia Molecular	Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
US5981215A (en) *	1995-06-06	1999-11-09	Human Genome Sciences, Inc.	Human criptin growth factor
IL127193A (en) *	1996-05-22	2006-10-31	Viventia Biotech Inc	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments and use thereof for the prophylaxis and detection of cancers
IL125608A0 (en)	1998-07-30	1999-03-12	Yeda Res & Dev	Tumor associated antigen peptides and use of same as anti-tumor vaccines
JP3793693B2 (ja)	1998-12-23	2006-07-05	ファイザーインコーポレーテッド	Ｃｔｌａ−４に対するヒトモノクローナル抗体
US6335170B1 (en) *	1999-02-22	2002-01-01	Torben F. Orntoft	Gene expression in bladder tumors
DK1167537T3 (da)	1999-03-30	2008-11-10	Japan Tobacco Inc	Fremgangsmåde til fremstilling af et monoklonalt antistof
AU4648900A (en) *	1999-04-20	2000-11-02	William J. Kokolus	Improved method of identifying and locating immunobiologically-active linear peptides
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2001046066A (ja)	1999-08-03	2001-02-20	Kyowa Hakko Kogyo Co Ltd	新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
ES2309012T3 (es)	1999-10-29	2008-12-16	Genentech, Inc.	Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
US6663613B1 (en)	2000-01-25	2003-12-16	Bacchus Vascular, Inc.	System and methods for clot dissolution
WO2001064754A1 (fr)	2000-03-03	2001-09-07	Kyowa Hakko Kogyo Co., Ltd.	Anticorps a recombinaison genique et son fragment
US6333410B1 (en) *	2000-08-18	2001-12-25	Immunogen, Inc.	Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en)	2000-08-24	2000-10-11	Smithkline Beecham Biolog	Vaccine
AU2001292724B2 (en) *	2000-09-18	2005-05-26	Biogen Idec Ma Inc.	CRIPTO mutant and uses thereof
CA2434694C (en)	2001-01-26	2012-09-18	Caterina Bianco	Detection and quantification of cripto-1
WO2002096948A2 (en)	2001-01-29	2002-12-05	Idec Pharmaceuticals Corporation	Engineered tetravalent antibodies and methods of use
BR0206985A (pt)	2001-01-29	2005-04-19	Idec Pharma Corp	Anticorpos modificados e métodos de uso
AUPR395801A0 (en)	2001-03-26	2001-04-26	Austin Research Institute, The	Antibodies against cancer
EA007469B1 (ru) *	2001-04-26	2006-10-27	Байоджен Айдек Эмэй Инк.	Антитела, блокирующие cripto, и их применения
US7582299B2 (en) *	2001-04-26	2009-09-01	Biogen Idec Ma Inc.	Cripto-specific antibodies
KR101008758B1 (ko) *	2001-09-18	2011-01-14	제넨테크, 인크.	종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20040014690A1 (en) *	2002-02-13	2004-01-22	Zhenkun Ma	Macrolides with activity against methicillin-resistant staphylococcus aureus
EP1494693B1 (en) *	2002-03-22	2010-12-08	Biogen Idec MA Inc.	Cripto-specific antibodies
DE602004022315D1 (de) *	2003-09-15	2009-09-10	Res Dev Foundation	Cripto-antagonismus von activin und tgf-b signalisierung
NZ556788A (en)	2005-01-05	2011-03-31	Biogen Idec Inc	Humanized CRIPTO binding molecules with CDRs from murine B3F6
EP2021510A2 (en)	2006-04-28	2009-02-11	Biogen Idec MA Inc.	Composition and methods for the detection of cripto-3

2002
- 2002-04-17 EA EA200301158A patent/EA007469B1/ru not_active IP Right Cessation
- 2002-04-17 SG SG200600551-6A patent/SG157951A1/en unknown
- 2002-04-17 SK SK1443-2003A patent/SK14432003A3/sk not_active Application Discontinuation
- 2002-04-17 DK DK02731384T patent/DK1390389T3/da active
- 2002-04-17 BR BRPI0209254-9A patent/BR0209254A/pt not_active IP Right Cessation
- 2002-04-17 HU HU0501113A patent/HUP0501113A3/hu unknown
- 2002-04-17 KR KR1020037014078A patent/KR100592357B1/ko not_active IP Right Cessation
- 2002-04-17 CZ CZ20033208A patent/CZ20033208A3/cs unknown
- 2002-04-17 JP JP2002585468A patent/JP4307845B2/ja not_active Expired - Fee Related
- 2002-04-17 CN CNB028128877A patent/CN100352501C/zh not_active Expired - Fee Related
- 2002-04-17 DE DE60230868T patent/DE60230868D1/de not_active Expired - Lifetime
- 2002-04-17 TR TR2003/01846T patent/TR200301846T2/xx unknown
- 2002-04-17 EP EP02731384A patent/EP1390389B1/en not_active Expired - Lifetime
- 2002-04-17 PL PL373513A patent/PL207087B1/pl unknown
- 2002-04-17 SI SI200230804T patent/SI1390389T1/sl unknown
- 2002-04-17 CA CA2443840A patent/CA2443840C/en not_active Expired - Fee Related
- 2002-04-17 CA CA2715570A patent/CA2715570A1/en not_active Abandoned
- 2002-04-17 AT AT02731384T patent/ATE420659T1/de active
- 2002-04-17 ES ES02731384T patent/ES2321065T3/es not_active Expired - Lifetime
- 2002-04-17 RS RS20110024A patent/RS20110024A/en unknown
- 2002-04-17 EP EP10186149A patent/EP2316486A3/en not_active Withdrawn
- 2002-04-17 WO PCT/US2002/011950 patent/WO2002088170A2/en active Search and Examination
- 2002-04-17 EP EP08158456A patent/EP1974749B1/en not_active Expired - Lifetime
- 2002-04-17 RS YU84903A patent/RS51635B/sr unknown
- 2002-04-17 GE GE5415A patent/GEP20074091B/en unknown
- 2002-04-17 PT PT02731384T patent/PT1390389E/pt unknown
- 2002-04-17 MX MXPA03009797A patent/MXPA03009797A/es active IP Right Grant
- 2002-04-17 EE EEP200300528A patent/EE200300528A/xx unknown
- 2002-04-17 AT AT08158456T patent/ATE533508T1/de active
- 2002-04-17 NZ NZ566268A patent/NZ566268A/en not_active IP Right Cessation
- 2002-04-23 MY MYPI20021484A patent/MY157382A/en unknown
- 2002-04-23 MY MYPI2010003173A patent/MY150237A/en unknown
- 2002-04-24 AR ARP020101492A patent/AR037223A1/es active IP Right Grant
2003
- 2003-10-23 US US10/693,538 patent/US7531174B2/en not_active Expired - Lifetime
- 2003-10-24 IS IS6999A patent/IS2662B/is unknown
- 2003-10-27 NO NO20034805A patent/NO20034805L/no not_active Application Discontinuation
- 2003-11-14 BG BG108363A patent/BG108363A/bg unknown
2004
- 2004-03-11 HK HK04101788.0A patent/HK1058935A1/xx not_active IP Right Cessation
2005
- 2005-07-11 JP JP2005202361A patent/JP2005314436A/ja active Pending
2007
- 2007-04-30 US US11/799,361 patent/US7674462B2/en not_active Expired - Lifetime
2008
- 2008-12-22 US US12/317,476 patent/US8003763B2/en not_active Expired - Lifetime
2009
- 2009-01-14 US US12/353,913 patent/US20090285818A1/en not_active Abandoned
- 2009-02-05 JP JP2009025420A patent/JP4575983B2/ja not_active Expired - Fee Related
- 2009-03-31 US US12/415,659 patent/US7888052B2/en not_active Expired - Lifetime
- 2009-04-08 CY CY20091100413T patent/CY1108960T1/el unknown
- 2009-07-08 AR ARP090102597A patent/AR072554A2/es not_active Application Discontinuation
- 2009-12-22 CL CL2009002199A patent/CL2009002199A1/es unknown
2010
- 2010-02-15 JP JP2010030683A patent/JP2010163438A/ja not_active Withdrawn
- 2010-07-16 AR ARP100102604A patent/AR077759A2/es not_active Application Discontinuation
2011
- 2011-08-19 US US13/213,499 patent/US8673303B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NZ566268A (en)	2009-09-25
EE200300528A (et)	2004-08-16
BR0209254A (pt)	2006-10-03
PT1390389E (pt)	2009-04-03
DK1390389T3 (da)	2009-04-20
CL2009002199A1 (es)	2010-05-07
HUP0501113A3 (en)	2007-12-28
WO2002088170A2 (en)	2002-11-07
TR200301846T2 (tr)	2006-10-26
GEP20074091B (en)	2007-04-25
AR077759A2 (es)	2011-09-21
NO20034805D0 (no)	2003-10-27
US20090285818A1 (en)	2009-11-19
CN1606453A (zh)	2005-04-13
EP2316486A3 (en)	2011-09-07
RS20110024A (xx)	2011-08-31
JP2010163438A (ja)	2010-07-29
EP1390389A2 (en)	2004-02-25
JP4575983B2 (ja)	2010-11-04
MY157382A (en)	2016-06-15
US20100202962A1 (en)	2010-08-12
CN100352501C (zh)	2007-12-05
ES2321065T3 (es)	2009-06-02
CA2443840C (en)	2010-10-26
SG157951A1 (en)	2010-01-29
SK14432003A3 (sk)	2004-07-07
US20040146940A1 (en)	2004-07-29
JP2004534020A (ja)	2004-11-11
EP1390389A4 (en)	2004-09-22
US7888052B2 (en)	2011-02-15
DE60230868D1 (de)	2009-03-05
WO2002088170A3 (en)	2003-12-24
US7531174B2 (en)	2009-05-12
YU84903A (sh)	2006-05-25
CA2715570A1 (en)	2002-11-07
KR100592357B1 (ko)	2006-06-22
KR20040028744A (ko)	2004-04-03
EA200301158A1 (ru)	2005-06-30
US7674462B2 (en)	2010-03-09
PL207087B1 (pl)	2010-10-29
EP1974749A1 (en)	2008-10-01
EA007469B1 (ru)	2006-10-27
NO20034805L (no)	2003-12-23
MY150237A (en)	2013-12-31
EP1974749B1 (en)	2011-11-16
JP2009108100A (ja)	2009-05-21
US20080166341A1 (en)	2008-07-10
EP2316486A2 (en)	2011-05-04
MXPA03009797A (es)	2004-01-29
CY1108960T1 (el)	2014-07-02
HK1058935A1 (en)	2004-06-11
JP4307845B2 (ja)	2009-08-05
AR037223A1 (es)	2004-11-03
JP2005314436A (ja)	2005-11-10
CA2443840A1 (en)	2002-11-07
US20090286265A1 (en)	2009-11-19
SI1390389T1 (sl)	2009-06-30
US8673303B2 (en)	2014-03-18
IS2662B (is)	2010-08-15
EP1390389B1 (en)	2009-01-14
US20120195912A1 (en)	2012-08-02
RS51635B (sr)	2011-08-31
HUP0501113A2 (en)	2007-05-02
US8003763B2 (en)	2011-08-23
PL373513A1 (en)	2005-09-05
CZ20033208A3 (en)	2004-03-17
ATE420659T1 (de)	2009-01-15
AR072554A2 (es)	2010-09-08
IS6999A (is)	2003-10-24
ATE533508T1 (de)	2011-12-15

Publication	Publication Date	Title
US7888052B2 (en)	2011-02-15	Cripto blocking antibodies and uses thereof
AU2002334799B2 (en)	2009-05-07	Cripto-specific antibodies
US7582299B2 (en)	2009-09-01	Cripto-specific antibodies
AU2007200809B2 (en)	2010-04-08	Cripto Blocking Antibodies and Uses Thereof
AU2002303364A1 (en)	2002-11-11	Cripto blocking antibodies and uses thereof
ZA200606338B (en)	2009-09-30	Cripto blocking antibodies and uses thereof
ES2355363T3 (es)	2011-03-25	Anticuerpos específicos de cripto.
AU2010202840A1 (en)	2010-07-22	Cripto Blocking Antibodies and Uses Thereof
NZ578287A (en)	2011-03-31	Cripto blocking antibodies and uses thereof